Empagliflozin Attenuates High-Glucose-Induced Astrocyte Activation and Inflammation via NF-κB Pathway
Current Issues in Molecular Biology · 04.11.2024 · 46 (11) · 12417-12427
DOI: 10.3390/cimb46110737 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 04.11.2024. Verfasst von Dong Hee Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50621, Republic of Korea. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pusan National University Yangsan Hospital, Research Institute for Convergence of Biomedical Science and Technology at Pusan National University Yangsan Hospital.
Abstract (Originalsprache)
Sodium-glucose cotransporter-2 (SGLT2) inhibitors regulate blood glucose levels in patients with type 2 diabetes mellitus and may also exert anti-inflammatory and anti-atherosclerotic effects by promoting M2 macrophage polarization. Although SGLT2 is expressed in brain regions that influence glucose balance and cognitive function, its roles in the central nervous system are unclear. This study investigated the effects of empagliflozin (EMPA), an SGLT2 inhibitor, on hypothalamic inflammation associated with metabolic diseases. Mice were subjected to a high-fat diet (HFD) for varying durations (3 d, 3 weeks, and 16 weeks) and treated with EMPA for 3 weeks (NFD, NFD + EMPA, HFD, HFD + EMPA; n = 5/group). EMPA regulated the expression of astrocyte markers and pro-inflammatory cytokine mRNA in the hypothalamus of HFD-induced mice, which was linked to regulation of the NF-κB pathway. Under hyperglycemic conditions, EMPA may mitigate hypothalamic inflammation by modulating astrocyte activation via the NF-κB pathway. Our findings demonstrated that EMPA possesses therapeutic potential beyond merely lowering blood glucose levels, opening new avenues for addressing inflammation and providing neuroprotection in metabolic disease management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50621, Republic of Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan 50621, Republic of Korea.
ORCID-Profile: Dong Hee Kim, Min Jin Lee, Dasol Kang, Ah Reum Khang, Yang Ho Kang, Dongwon Yi
Förderung
- Pusan National University Yangsan Hospital
- Research Institute for Convergence of Biomedical Science and Technology at Pusan National University Yangsan Hospital
Zitieren
APA
Kim, D. H., Lee, M. J., Kang, D., Lee, J. Y., Park, S., Khang, A. R., Bae, J. H., Kim, J. Y., Kim, S. H., Kang, Y. H., & Yi, D. (2024). Empagliflozin Attenuates High-Glucose-Induced Astrocyte Activation and Inflammation via NF-κB Pathway. Current Issues in Molecular Biology, 46(11), 12417-12427. https://doi.org/10.3390/cimb46110737
Vancouver
Kim DH, Lee MJ, Kang D, Lee JY, Park S, Khang AR, et al. Empagliflozin Attenuates High-Glucose-Induced Astrocyte Activation and Inflammation via NF-κB Pathway. Current Issues in Molecular Biology. 2024;46(11):12417-12427. doi:10.3390/cimb46110737
BibTeX
@article{Kim2024,
author = {Kim, Dong Hee and Lee, Min Jin and Kang, Dasol and Lee, Ji Young and Park, Sujin and Khang, Ah Reum and Bae, Ji Hyun and Kim, Joo Yeon and Kim, Su Hyun and Kang, Yang Ho and Yi, Dongwon},
title = {Empagliflozin Attenuates High-Glucose-Induced Astrocyte Activation and Inflammation via NF-κB Pathway},
journal = {Current Issues in Molecular Biology},
year = {2024},
volume = {46},
number = {11},
pages = {12417--12427},
doi = {10.3390/cimb46110737}
}
EUVIMED